Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. W.W.H. Roeloffzen

Publicaties

Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Successful Desensitization to Isatuximab in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis Reply to: Anaphylactic Shock due to Isatuximab and Successful Desensitization

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands